# Felcisetrag stimulates 5-HT4-serotonin receptors in the human atrium

**Authors:** Lina Maria Rayo Abella, Joachim Neumann, Britt Hofmann, Uwe Kirchhefer, Ulrich Gergs

PMC · DOI: 10.1007/s00210-025-04606-w · Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-09-29

## TL;DR

Felcisetrag affects heart muscle contractions by interacting with serotonin receptors in human and mouse atria.

## Contribution

Felcisetrag is shown to act as both an agonist and antagonist of 5-HT4 receptors in the heart.

## Key findings

- Felcisetrag increases heart muscle contraction in mice with human 5-HT4 receptor overexpression.
- The drug's effects are blocked by a 5-HT4 receptor antagonist, GR125487.
- Felcisetrag's action in human atria is modulated by cilostamide and serotonin.

## Abstract

Felcisetrag (methyl 4-[[4-[[(2-propan-2-yl-1H-benzimidazole-4-carbonyl)-amino]-methyl]-piperidin-1-yl]methyl]piperidine-1-carboxylate, TD-8954, TAK-954) has a structural formula with similarity to serotonin. It is one of the most potent compounds to bind to recombinant human 5-HT4-serotonin receptors. We noted that felcisetrag raised force of contraction in left atrial preparations (LA) and beating rate in right atrial preparations (RA) from mice with cardiac-specific overexpression of the human 5-HT4 receptors (5-HT4-TG) but was inactive in LA and RA from adult wild type mouse hearts (WT). When felcisetrag had increased force of contraction in LA or beating rate in RA of 5-HT4-TG, GR125487, a 5-HT4 receptor antagonist, reduced force of contraction and beating rate. Felcisetrag raised force of contraction only in the presence of cilostamide in human right atrial preparations (HAP) obtained from adult patients during open heart surgery due to severe coronary heart disease. These positive inotropic effects of felcisetrag in HAP were attenuated by 1 µM GR125487. In the presence of cilostamide, 100 nM felcisetrag exerted positive inotropic effects that were increased further by 1 µM serotonin. When 1 µM serotonin had raised force of contraction, additionally applied 100 nM felcisetrag reduced force of contraction in HAP. These data suggest that felcisetrag can act as an agonist as well as an antagonist at human 5-HT4 receptors in the mammalian heart.

## Linked entities

- **Proteins:** HTR4 (5-hydroxytryptamine receptor 4)
- **Chemicals:** Felcisetrag (PubChem CID 11961293), GR125487 (PubChem CID 4284721), cilostamide (PubChem CID 2753), serotonin (PubChem CID 5202)
- **Diseases:** coronary heart disease (MONDO:0005010)
- **Species:** Mus musculus (taxon 10090), Homo sapiens (taxon 9606)

## Full-text entities

- **Diseases:** coronary heart disease (MESH:D003327)
- **Chemicals:** 5-HT4-TG (-), GR125487 (MESH:C082871), Felcisetrag (MESH:C581614), serotonin (MESH:D012701), cilostamide (MESH:C021294)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** HAP — Homo sapiens (Human), Finite cell line (CVCL_ZG36)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12935854/full.md

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12935854/full.md

---
Source: https://tomesphere.com/paper/PMC12935854